 HOOKIPA Pharma Inc. NASDAQ: HOOK, HOOKIPA, a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reports its financial results and corporate update for the first quarter ended March 31, 2020. For HB-101, although enrollment of kidney transplant patients is currently hampered by the impact of COVID-19, we expect to report preliminary safety and immunogenicity data in July 2020 and efficacy data by the end of 2020, roughly at the same time we expect to report preliminary safety and efficacy for HB-201. HOOKIPAs VaxWave-based prophylactic Cytomegalovirus CMV vaccine candidate, HB101, is in a randomized, doubleblinded Phase 2 clinical trial in patients awaiting kidney transplantation who are at risk for CMV-associated complications post-transplant. 